| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCIENCE.271.5253.1282 |
| P698 | PubMed publication ID | 8638110 |
| P2093 | author name string | Q Song | |
| Z Gu | |||
| M A Wainberg | |||
| G Borkow | |||
| H Salomon | |||
| S Islam | |||
| M Hsu | |||
| V R Prasad | |||
| J Manne | |||
| G Castriota | |||
| W C Drosopoulos | |||
| M Parniak | |||
| P433 | issue | 5253 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1282-1285 | |
| P577 | publication date | 1996-03-01 | |
| P1433 | published in | Science | Q192864 |
| P1476 | title | Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase | |
| P478 | volume | 271 |
| Q30453467 | 3'-Azido-3'-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1. |
| Q28379497 | 3'-Azido-3'-deoxythymidine (AZT) mediates cross-resistance to nucleoside analogs in the case of AZT-resistant human immunodeficiency virus type 1 variants. |
| Q39516070 | A mutation in the primer grip region of HIV-1 reverse transcriptase that confers reduced fidelity of DNA synthesis |
| Q35879410 | A novel Met-to-Thr mutation in the YMDD motif of reverse transcriptase from feline immunodeficiency virus confers resistance to oxathiolane nucleosides |
| Q33782477 | A novel point mutation at position 156 of reverse transcriptase from feline immunodeficiency virus confers resistance to the combination of (-)-beta-2',3'-dideoxy-3'-thiacytidine and 3'-azido-3'-deoxythymidine |
| Q44809166 | A pilot phase II study of the safety and immunogenicity of HIV p17/p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects. |
| Q35163547 | A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity |
| Q38915386 | Adenovirus expressing a bioluminescence reporter gene and cMAGI cell assay for the detection of HIV-1. |
| Q39595957 | Altering the intracellular environment increases the frequency of tandem repeat deletion during Moloney murine leukemia virus reverse transcription |
| Q34396299 | Analysis of a comprehensive dataset of diversity generating retroelements generated by the program DiGReF. |
| Q41116397 | Antiretroviral drugs for AIDS. |
| Q24234853 | Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy |
| Q24635860 | Arbovirus high fidelity variant loses fitness in mosquitoes and mice |
| Q35899105 | Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. |
| Q35266435 | Biochemical impact of the host adaptation-associated PB2 E627K mutation on the temperature-dependent RNA synthesis kinetics of influenza A virus polymerase complex |
| Q36368294 | Biochemical mechanism of HIV-1 resistance to rilpivirine |
| Q35633587 | Biochemical, inhibition and inhibitor resistance studies of xenotropic murine leukemia virus-related virus reverse transcriptase |
| Q36203142 | Bioinformatic Identification of Rare Codon Clusters (RCCs) in HBV Genome and Evaluation of RCCs in Proteins Structure of Hepatitis B Virus |
| Q38752758 | Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, o |
| Q36969857 | Clinical significance of human immunodeficiency virus type 1 replication fitness |
| Q37404676 | Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R+74V. |
| Q42929822 | Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021). |
| Q45484175 | Comparison of DNA polymerase activities between recombinant feline immunodeficiency and leukemia virus reverse transcriptases |
| Q33971104 | Comparison of DNA sequencing and a line probe assay for detection of human immunodeficiency virus type 1 drug resistance mutations in patients failing highly active antiretroviral therapy |
| Q36747913 | Comparison of G-to-A mutation frequencies induced by APOBEC3 proteins in H9 cells and peripheral blood mononuclear cells in the context of impaired processivities of drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants |
| Q36689086 | Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors |
| Q53704198 | Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. |
| Q33938993 | DNA synthesis fidelity by the reverse transcriptase of the yeast retrotransposon Ty1. |
| Q33794922 | Development of an in vivo assay to identify structural determinants in murine leukemia virus reverse transcriptase important for fidelity |
| Q45393864 | Development of resistance of human immunodeficiency virus (HIV) to anti-HIV agents: how to prevent the problem? |
| Q28484213 | Differential in vitro kinetics of drug resistance mutation acquisition in HIV-1 RT of subtypes B and C |
| Q39796529 | Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity |
| Q47681935 | Dominance of the E89G substitution in HIV-1 reverse transcriptase in regard to increased polymerase processivity and patterns of pausing |
| Q34973832 | Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing. |
| Q33807866 | Effects of amino acid substitutions at position 115 on the fidelity of human immunodeficiency virus type 1 reverse transcriptase |
| Q33967135 | Evidence for the adaptive evolution of mutation rates |
| Q33823310 | Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. |
| Q34094904 | Evolutionary changes in mutation rates and spectra and their influence on the adaptation of pathogens |
| Q39603104 | Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV. |
| Q38363496 | Exploring the effects of active site constraints on HIV-1 reverse transcriptase DNA polymerase fidelity |
| Q54386002 | Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. |
| Q38616021 | Fidelity Variants and RNA Quasispecies. |
| Q64932653 | Fidelity analysis of HIV-1 reverse transcriptase mutants with an altered amino-acid sequence at residues Leu74, Glu89, Tyr115, Tyr183 and Met184. |
| Q42047382 | Fidelity of hepatitis B virus polymerase |
| Q38330800 | Functional analysis of amino acid residues constituting the dNTP binding pocket of HIV-1 reverse transcriptase |
| Q47560008 | Genotypic and Phylogenetic Insights on Prevention of the Spread of HIV-1 and Drug Resistance in "Real-World" Settings |
| Q39557921 | Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy |
| Q33906239 | Genotypic testing for human immunodeficiency virus type 1 drug resistance |
| Q80098606 | HIV resistance to antiviral drugs: public health implications |
| Q33758570 | HIV-1 Transmission, Replication Fitness and Disease Progression |
| Q38295770 | HIV-1 nucleocapsid protein and the secondary structure of the binary complex formed between tRNA(Lys.3) and viral RNA template play different roles during initiation of (-) strand DNA reverse transcription |
| Q34769839 | High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia |
| Q35597143 | High frequency of functional anti-YMDD and -mutant cytotoxic T lymphocytes after in vitro expansion correlates with successful response to lamivudine therapy for chronic hepatitis B |
| Q35156558 | High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis. |
| Q34644794 | Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1. |
| Q39880572 | Homologous recombination occurs in a distinct retroviral subpopulation and exhibits high negative interference |
| Q33686694 | Human hepatitis B virus mutants: significance of molecular changes |
| Q35907177 | Human immunodeficiency virus type 1 reverse transcriptase: role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesis |
| Q44160944 | Identification of a simian immunodeficiency virus reverse transcriptase variant with enhanced replicational fidelity in the late stage of viral infection. |
| Q37409900 | Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile |
| Q35375912 | In search of a selective antiviral chemotherapy. |
| Q39463811 | In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure |
| Q33782815 | Increased misincorporation fidelity observed for nucleoside analog resistance mutations M184V and E89G in human immunodeficiency virus type 1 reverse transcriptase does not correlate with the overall error rate measured in vitro |
| Q39875329 | Increased polymerase fidelity of E89G, a nucleoside analog-resistant variant of human immunodeficiency virus type 1 reverse transcriptase. |
| Q39720877 | Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase |
| Q34050684 | Inhibitors of HIV-1 reverse transcriptase |
| Q80215893 | Inhibitors of HIV-1 reverse transcriptase |
| Q38342940 | Interaction of retroviral reverse transcriptase with template-primer duplexes during replication. |
| Q42705384 | Intermediate mutation frequencies favor evolution of multidrug resistance in Escherichia coli |
| Q41888126 | Interrelationship between HIV-1 fitness and mutation rate. |
| Q39740543 | Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation |
| Q41429010 | Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection |
| Q39785298 | Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptase |
| Q93122212 | Linked dual-class HIV resistance mutations are associated with treatment failure |
| Q33588535 | Managing resistance to anti-HIV drugs: an important consideration for effective disease management. |
| Q36648368 | Mechanisms of clinical resistance by HIV-I variants to zidovudine and the paradox of reverse transcriptase sensitivity |
| Q28302073 | Mechanistic differences in RNA-dependent DNA polymerization and fidelity between murine leukemia virus and HIV-1 reverse transcriptases |
| Q39719540 | Mispair extension fidelity of human immunodeficiency virus type 1 reverse transcriptases with amino acid substitutions affecting Tyr115. |
| Q34725650 | Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases |
| Q35566910 | Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase |
| Q35579833 | Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1 |
| Q33873983 | Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture |
| Q34992731 | Mutation V111I in HIV-2 reverse transcriptase increases the fitness of the nucleoside analogue-resistant K65R and Q151M viruses |
| Q37945186 | Mutation rates and intrinsic fidelity of retroviral reverse transcriptases. |
| Q40714016 | Mutational analysis of HIV-1 long terminal repeats to explore the relative contribution of reverse transcriptase and RNA polymerase II to viral mutagenesis |
| Q45768857 | Mutational studies of human immunodeficiency virus type 1 reverse transcriptase: the involvement of residues 183 and 184 in the fidelity of DNA synthesis |
| Q33743954 | Mutations in HIV-1 reverse transcriptase affect the errors made in a single cycle of viral replication |
| Q73019259 | Mutations in the primer grip region of HIV reverse transcriptase can increase replication fidelity |
| Q34976998 | Mutations proximal to the minor groove-binding track of human immunodeficiency virus type 1 reverse transcriptase differentially affect utilization of RNA versus DNA as template |
| Q38353178 | Negative effect of the M184V mutation in HIV-1 reverse transcriptase on initiation of viral DNA synthesis |
| Q27480816 | Negative effects of chemical mutagenesis on the adaptive behavior of vesicular stomatitis virus |
| Q38320544 | New human immunodeficiency virus, type 1 reverse transcriptase (HIV-1 RT) mutants with increased fidelity of DNA synthesis. Accuracy, template binding, and processivity |
| Q24817042 | Nucleotide modification at the gamma-phosphate leads to the improved fidelity of HIV-1 reverse transcriptase. |
| Q35890905 | Nucleotide substitutions within U5 are critical for efficient reverse transcription of human immunodeficiency virus type 1 with a primer binding site complementary to tRNA(His) |
| Q40863517 | Pathways to extinction: beyond the error threshold |
| Q34677368 | Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity. |
| Q33631716 | Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection |
| Q74447294 | Probing interactions between HIV-1 reverse transcriptase and its DNA substrate with backbone-modified nucleotides |
| Q36419489 | Recombination between variants from genital tract and plasma: evolution of multidrug-resistant HIV type 1 |
| Q35905947 | Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. |
| Q40802197 | Resolution of Specific Nucleotide Mismatches by Wild-Type and AZT-Resistant Reverse Transcriptases during HIV-1 Replication |
| Q27470003 | Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity |
| Q37722585 | Retroviral reverse transcriptases |
| Q51003294 | Reverse Transcription of Retroviruses and LTR Retrotransposons. |
| Q34465037 | Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. |
| Q34386057 | Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages |
| Q44481687 | Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance |
| Q33787219 | Role of murine leukemia virus reverse transcriptase deoxyribonucleoside triphosphate-binding site in retroviral replication and in vivo fidelity. |
| Q35659212 | Site-directed mutagenesis in the fingers subdomain of HIV-1 reverse transcriptase reveals a specific role for the beta3-beta4 hairpin loop in dNTP selection |
| Q44225811 | Site-specific incorporation of nucleoside analogs by HIV-1 reverse transcriptase and the template grip mutant P157S. Template interactions influence substrate recognition at the polymerase active site |
| Q27676135 | Structural analysis of monomeric retroviral reverse transcriptase in complex with an RNA/DNA hybrid |
| Q43955772 | Substitutions of Phe61 located in the vicinity of template 5'-overhang influence polymerase fidelity and nucleoside analog sensitivity of HIV-1 reverse transcriptase |
| Q37018369 | The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. |
| Q39590457 | The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis |
| Q39776171 | The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates |
| Q33815628 | The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities |
| Q41808090 | The active site residue Valine 867 in human telomerase reverse transcriptase influences nucleotide incorporation and fidelity |
| Q28378929 | The antiretrovirus drug 3'-azido-3'-deoxythymidine increases the retrovirus mutation rate |
| Q24534107 | The frameshift signal of HIV-1 involves a potential intramolecular triplex RNA structure |
| Q38878591 | The glutamine side chain at position 91 on the β5a-β5b loop of human immunodeficiency virus type 1 reverse transcriptase is required for stabilizing the dNTP binding pocket. |
| Q38158093 | The high cost of fidelity |
| Q33783072 | The impact of multidideoxynucleoside resistance-conferring mutations in human immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and error specificity |
| Q34668716 | The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase |
| Q38021263 | The origin of genetic diversity in HIV-1. |
| Q39723479 | The processivity of DNA synthesis exhibited by drug-resistant variants of human immunodeficiency virus type-1 reverse transcriptase |
| Q54123440 | The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. |
| Q33976004 | The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3'-azido-3'-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. |
| Q33788626 | Therapy of chronic hepatitis B virus infection: inhibition of the viral polymerase and other antiviral strategies |
| Q50132690 | To be a mutator, or how pathogenic and commensal bacteria can evolve rapidly |
| Q49380562 | Towards a universal second-line fixed-dose combination ART. |
| Q28478656 | Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load |
| Q35827900 | Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period |
| Q33846297 | Tribute to Mark Wainberg |
| Q38318740 | Uniquely altered DNA replication fidelity conferred by an amino acid change in the nucleotide binding pocket of human immunodeficiency virus type 1 reverse transcriptase |
| Q31047702 | Unselected mutations in the human immunodeficiency virus type 1 genome are mostly nonsynonymous and often deleterious |
| Q37034618 | Viral drug resistance and fitness. |
| Q27013917 | Viral quasispecies evolution |
| Q39065035 | Viral reverse transcriptases. |
| Q34339657 | Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase |
| Q43514301 | Virus mutators and antimutators: roles in evolution, pathogenesis and emergence |
| Q33853661 | YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection |
Search more.